Skip to content Skip to sidebar Skip to footer

Newsletter

Mining Stocks

Gold 2026 Predictions: Why Big Money Thinks Gold’s Best Days Are Still Ahead

Gold 2026 Predictions: Continued Winning When Confidence Breaks With gold remaining one of the most closely followed commodities among investors, we wanted to step back and understand what high quality, large institutions are forecasting for gold prices and why the outlook continues to attract so much attention. Gold has long played a unique role in financial…

ByCharlie YouldenJanuary 15, 20260Comments

Tech Stocks Technology

DataWorks Group (ASX:DWG) The Quarter Cash Flow Finally Turned

The Inflection Point Investors Were Waiting For DataWorks Group Limited (ASX:DWG) delivered a strong December quarter result, which saw the share price re rate by around 20% on the day. We think the result marks an important turning point for the business after a prolonged period of cash burn. Customer receipts reached approximately A$3 million during…

ByCharlie YouldenJanuary 15, 20260Comments

Cryptocurrencies

How Institutions Are Changing Crypto Investing

Cryptocurrency is no longer a niche idea. What initially began as an experiment has become a significant asset class and has a large number of connections with conventional finance. To meet investor demand for insight into how blockchain-based assets can be used into diversified portfolios, the current environment provides the opportunity and clarity today, as…

ByUjjwal MaheshwariJanuary 15, 20260Comments

Lithium Stocks

PLS Group (ASX:PLS) Surges to 52-Week High After 167% Lithium Rally: Buy or Wait?

PLS Group Soars as Lithium Recovery Gains Momentum PLS Group (ASX: PLS), formerly known as Pilbara Minerals, hit a fresh 52-week high of A$4.94 this week as lithium prices surged to their best levels since late 2023. The rally started after China said it would remove tax rebates for battery exports. Since mid-2025, lithium prices…

ByUjjwal MaheshwariJanuary 15, 20260Comments

Healthcare Stocks

5 ASX Healthcare Companies with Game Changing Milestones in 2026!

2026 is set to be a big year for several ASX Healthcare Companies, especially companies in the pre-commercialisation stage. The two keys to get drugs or devices to market are to pass clinical trials and obtain regulatory approval. This article takes a look at 5 of the most exciting of those companies. What are the Best…

ByNick SundichJanuary 15, 20260Comments

Blue Chip Stocks Consumer International Stocks

QBE Insurance Group (ASX:QBE): Is this the 4-decade long Sydney Swans sponsor the ASX insurer to buy?

If you're a fan of sport, you'd know that QBE Insurance Group (ASX:QBE) have been a sponsor of the Sydney Swans for over 40 years - one of the longest-running sponsorships in global sport. One not knowing anything else about the company would have to assume it must be doing something right to survive as long…

ByNick SundichJanuary 15, 20260Comments

Uranium Stocks

Deep Yellow (ASX:DYL) Fast-Tracks New CEO Ahead of Tumas FID : Should You Buy Now?

Deep Yellow Brings CEO Forward as Tumas FID Nears Deep Yellow (ASX:DYL) shares are trading at A$2.03, up more than 70% over the past year. The uranium developer just announced it's bringing forward its new CEO's start date by three months. Greg Field will now begin on February 2, 2026, instead of the originally planned…

ByUjjwal MaheshwariJanuary 15, 20260Comments

Copper Stocks

Norfolk Metals (ASX:NFL) Confirms High-Grade Copper in Chile: Is This A$8M Explorer a Buy?

Norfolk Metals Hits High-Grade Copper in Chile Norfolk Metals (ASX: NFL) is making waves after releasing impressive copper results from its first drilling campaign at the Carmen Copper Project in Chile. The standout hit was 32 metres grading 1.3% copper from just 97 metres below the surface, with mineralisation still open at depth. The company…

ByUjjwal MaheshwariJanuary 15, 20260Comments

Biotech Stocks

Neuren Pharmaceuticals (ASX:NEU) Surges 6% on US$700m DAYBUE Target: Time to Buy?

DAYBUE royalties could climb fast if US targets land Neuren Pharmaceuticals (ASX: NEU) jumped 6% on Wednesday after its US partner, Acadia Pharmaceuticals, shared big news at the J.P. Morgan Healthcare Conference. Acadia now expects DAYBUE sales to hit US$700 million by 2028, sending Neuren shares to around A$20.47. The stock has climbed more than…

ByUjjwal MaheshwariJanuary 15, 20260Comments

the Kick-ass Multipurpose WordPress Theme

Gold 2026 Predictions: Why Big Money Thinks Gold’s Best Days Are Still Ahead

DataWorks Group (ASX:DWG) The Quarter Cash Flow Finally Turned

How Institutions Are Changing Crypto Investing

PLS Group (ASX:PLS) Surges to 52-Week High After 167% Lithium Rally: Buy or Wait?

5 ASX Healthcare Companies with Game Changing Milestones in 2026!

QBE Insurance Group (ASX:QBE): Is this the 4-decade long Sydney Swans sponsor the ASX insurer to buy?

Deep Yellow (ASX:DYL) Fast-Tracks New CEO Ahead of Tumas FID : Should You Buy Now?

Norfolk Metals (ASX:NFL) Confirms High-Grade Copper in Chile: Is This A$8M Explorer a Buy?

Neuren Pharmaceuticals (ASX:NEU) Surges 6% on US$700m DAYBUE Target: Time to Buy?

Weebit Nano (ASX:WBT) is getting ready for the big time with an $80m capital raise!

BluGlass presented at the Pitt Street Research Semiconductor Conference 2026

Weebit Nano presented at the Pitt Street Research Semiconductor Conference 2026

Nanoveu presented at the Pitt Street Research Semiconductor Conference 2026

Archer Materials presented at the Pitt Street Research Semiconductor Conference 2026

2020, the Golden Year

Investing in the Year of the Rat

Market trouble spots to avoid in 2020

Add Your Heading Text Here